Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeks
November 4, 2009Researchers at Fox Chase Cancer Center found that radiation treatment for women who had a lumpectomy for early-stage breast cancer can be safely reduced to four weeks, instead of the usual six to seven weeks, by delivering a higher daily dose--greatly reducing the length of treatment time. The five-year results of the phase II study will be presented today at the annual meeting of the American Society for Radiation Oncology.
The study showed that treatment time can be shortened from the historical six to seven weeks to just four weeks using IMRT (intensity-modulated radiation therapy), a highly sophisticated system of delivering external-beam radiation. This system uses advanced computer optimized planning and radiation delivery techniques that create more optimal dose distributions, greater sparing of the skin and lower doses to organs such as lung and heart--thus reducing potential side effects.
"When delivering high doses of radiation, we have to consider the level of side effects and the cosmetic result," explained Gary Freedman, M.D., radiation oncologist at Fox Chase. "In this phase II study, women reported acceptable side effects that were no different than would be expected from a usual, more prolonged length of treatment. In addition, with long term follow-up we see cure rates and cosmetic results that are similar to a longer six-week treatment course."
Using IMRT, this study examined the delivery of a higher daily dose of radiation over four weeks (versus a lower dose over six to seven weeks). Another way of reducing treatment length was by incorporating a "boost" into the same four weeks. The lumpectomy site where the tumor was removed is usually treated with a high-dose radiation "boost." The standard "boost" is typically administered after the five weeks of whole breast irradiation and can add another one to two weeks to the treatment time.
Freedman and his colleagues demonstrated that in addition to safely increasing the dose to the whole breast during the four-week period, it is possible to deliver the "boost" concurrently, eliminating the extra two weeks.
"This more accelerated treatment regimen should be an option for women who want to be treated in a shorter period of time," says Freedman. "This may particularly appeal to women who drive a long distance for radiation, have busy schedules at home or work, or have a large insurance co-pay for each daily radiation treatment."
Freedman cautioned that this treatment schedule may not be for all women. "There may be patients who are uncomfortable with the idea of an accelerated treatment and want to be treated with a more conventional six to seven week course of treatment," he says. "In addition, we need more research to determine which women are ideal candidates for this treatment because of differences in anatomy or other treatments for their breast cancer."
The study included 75 women treated with 2.25 Gy for 20 days (versus 2 Gy per day with conventional therapy) and a 2.8 Gy boost concurrently (versus sequentially delivering the boost after whole breast irradiation). The risk of recurrence within five years in the treated breast was low-0.4%--which compares favorably to results with conventional radiation. In addition, patients and their physicians considered the cosmetic results good or excellent in most women.
-
Increasing radiation dose shortens treatment time for women who choose breast sparing treatment
May 29, 2007 |
not rated yet |
0
-
Breast cancer treatment offers better outcome to women with implants
Dec 01, 2008 |
not rated yet |
0
-
Young women w/ early form of breast cancer no more likely to experience recurrence than older women
Sep 24, 2008 |
not rated yet |
0
-
Breast cancer survivors have high quality of life up to 15 years after lumpectomy/radiation
Sep 21, 2008 |
not rated yet |
0
-
Younger breast cancer patients have greater chance of recurrence
Mar 04, 2009 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (31) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Study finds that anti-diabetic medication can prevent the long-term effects of maternal obesity
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication ...
16 hours ago |
5 / 5 (1) |
1
Steroid injections prove effective in treatment of lumbar disc herniations
The use of epidural steroid injections may be a more efficient treatment option for lumbar disc herniations, according to research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in ...
16 hours ago |
5 / 5 (1) |
0
Amateur football players not always keen on returning to play after ACL injuries
Despite the known success rates of reconstructive Anterior Cruciate Ligament (ACL) surgery, the number of high school and collegiate football players returning to play may not be as high as anticipated, say researchers presenting ...
16 hours ago |
not rated yet |
0
FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice
Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...
Medicine & Health / Neuroscience
Feb 09, 2012 |
4.9 / 5 (51) |
20
|
Study finds elevated levels of cell-free DNA in first trimester do not predict preeclampsia
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that indicate that elevated levels of cell-free DNA in ...
16 hours ago |
not rated yet |
0
Walney offshore wind farm is world's biggest (for now)
(PhysOrg.com) -- The Walney wind farm on the Irish Sea--characterized by high tides, waves and windy weather--officially opened this week. The farm is treated in the press as a very big deal as the Walney ...
GPS court ruling leaves US phone tracking unclear
A US Supreme Court decision requiring a warrant to place a GPS device on the car of a criminal suspect leaves unresolved the bigger issue of police tracking using mobile phones, legal experts say.
Europeans protest controversial Internet pact
Tens of thousands of people marched in protests in more than a dozen European cities Saturday against a controversial anti-online piracy pact that critics say could curtail Internet freedom.
Europe stakes billion-dollar bet on new rocket
A pencil-slim rocket is scheduled to lift into space from South America on Monday, carrying a billion-dollar bet that Europe can grab a juicy slice of the market to place satellites in low orbit.
Netflix settlement trims 14 pct off 4Q earnings
(AP) -- Netflix pressed the rewind button on its fourth-quarter earnings after settling allegations that the video subscription service violated a consumer-privacy law.
Navy to begin tests on electromagnetic railgun prototype launcher
The Office of Naval Research (ONR)'s Electromagnetic (EM) Railgun program will take an important step forward in the coming weeks when the first industry railgun prototype launcher is tested at a facility ...